Last reviewed · How we verify
DC-CIK
DC-CIK is a dendritic cell-cytokine induced killer cell immunotherapy that activates and expands autologous immune cells to target and destroy cancer cells.
DC-CIK is a dendritic cell-cytokine induced killer cell immunotherapy that activates and expands autologous immune cells to target and destroy cancer cells. Used for Hepatocellular carcinoma, Gastric cancer, Colorectal cancer.
At a glance
| Generic name | DC-CIK |
|---|---|
| Also known as | 1 |
| Sponsor | Guangxi Medical University |
| Drug class | Autologous cellular immunotherapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DC-CIK combines dendritic cells (antigen-presenting cells) with cytokine-induced killer cells to create a personalized cellular immunotherapy. The dendritic cells are loaded with tumor antigens to prime immune recognition, while the CIK cells provide cytotoxic effector function. This combination aims to enhance anti-tumor immunity by bridging innate and adaptive immune responses.
Approved indications
- Hepatocellular carcinoma
- Gastric cancer
- Colorectal cancer
Common side effects
- Fever
- Chills
- Fatigue
- Infusion-related reactions
Key clinical trials
- Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer. (EARLY_PHASE1)
- Immune Cell Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML (PHASE1, PHASE2)
- Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma (PHASE1, PHASE2)
- Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy (NA)
- Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer (NA)
- Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |